Fig. 5: Protection against SARS-CoV-2 virus challenge in hamsters through prime-boost immunization with BNT162b2 mRNA or DelNS1-RBD4N-DAF vaccines. | Nature Communications

Fig. 5: Protection against SARS-CoV-2 virus challenge in hamsters through prime-boost immunization with BNT162b2 mRNA or DelNS1-RBD4N-DAF vaccines.

From: An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters

Fig. 5: Protection against SARS-CoV-2 virus challenge in hamsters through prime-boost immunization with BNT162b2 mRNA or DelNS1-RBD4N-DAF vaccines.

A Illustration of schedule of immunization, blood collection and SARS-CoV-2 virus challenge for hamsters. Hamsters were prime-boost vaccinated either intranasally with Delta4N-DAF (5 × 106 pfu), Omi4N-DAF (5 × 106 pfu), DelNS1 vector (5 × 106 pfu) or PBS (mock) or intramuscularly with BNT162b2 mRNA (1/6 clinical dose (5ug)) vaccine. Hamsters were challenged with SARS-CoV-2 variants Delta or Omicron BA.2 at 1 × 104 pfu per hamster, 4 weeks after boost immunization. Body weight changes following SARS-CoV-2 virus challenge of hamsters immunized with Delta4N-DAF, Omi4N-DAF or BNT162b2 mRNA vaccines or controls (n = 4 for each group) (B, D, and F). Virus titers in the lungs and nasal turbinates (NT) of hamsters were measured at 4 dpi (n = 4 for each group) (C, E, and G). NT nasal turbinates. LOD lower limit of detection. Error bars represent mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Dunn’s multiple comparisons test: ****p < 0.0001, *p < 0.05, ns not significant. Hamster cartoon created with BioRender.com.

Back to article page